• (PLX AI) – MorphoSys outlook FY revenue now EUR 155-180 million vs EUR 150-200 million previously.
  • • The updated revenue guidance primarily reflects updated Monjuvi(R) product sales expectations
  • • MorphoSys also sees higher costs: Group operating expenses, which is comprised of R&D and Selling, as well as General & Administrative expenses, in the range of € 435 to € 465 million (previously: € 355 to € 385 million)
  • • Shares down 4%

Quelle: PLX AI